MOUD Buprenorphine Sublocade denied for missing prior authorization by Express Scripts?
If the original prescription wasn't run through prior auth, the path is to submit a PA now with a medical-necessity letter — many plans then back-date approval to the date of service.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Express Scripts typically requires
Sublocade requires 7+ days sublingual buprenorphine stabilization before LA injectable approved.
What works in the appeal
Patient-specific justification: prior buprenorphine non-adherence, diversion concerns, work/travel adherence challenges, prior overdose, pregnancy. ASAM NPG OUD 2020. Cite HOFER pivotal (Haight 2019, Lancet). MHPAEA 2024 Final Rule NQTL — demand comparative analysis.
The Express Scripts angle on MOUD Buprenorphine Sublocade
## Why Express Scripts Requires Prior Authorization for Sublocade — and How to Succeed
Express Scripts (ESI) requires prior authorization (PA) for Sublocade (buprenorphine extended-release subcutaneous injection) across most of the health plans it administers. This is a routine utilization management step — not an unusual barrier — but PA denials or lapses are common and create significant treatment disruptions for patients with opioid use disorder. Understanding exactly what ESI needs, and providing it completely at the first submission, is the key to avoiding multiple rounds of appeals.
Prior-auth-required denials occur when: (a) no PA was submitted before dispensing, (b) a submitted PA was incomplete or missing required clinical information, (c) the PA was submitted by the pharmacy rather than the treating clinician and lacked clinical documentation, or (d) an existing PA expired without timely renewal.
## Federal Appeal Rights
- Internal appeal (ACA §2719 / ERISA §503): If a PA request is denied (not just pending), you have 180 days to file an internal appeal. Plans must respond within 30 days (pre-service).
- Expedited review: For urgent situations — including a patient already on treatment whose PA lapsed — request expedited review with a 72-hour response requirement.
- External independent review (ACA §2719): If the internal appeal fails, external review is available. You have approximately four months from the denial to initiate it. External reviewers assess whether the PA denial was clinically appropriate under the plan's own criteria.
- MHPAEA: If PA requirements for Sublocade are more burdensome than PA requirements for comparable medical or surgical treatments, a parity argument is available and should be raised.
## The Appeal Process
1. Obtain ESI's PA criteria for Sublocade — these must be disclosed on request. Read them carefully before submitting the appeal. 2. Identify why the original PA was denied — missing documentation, failed criteria, or procedural lapse. 3. Gather complete documentation (see below) and submit a new PA or appeal letter that addresses every criterion. 4. Request peer-to-peer review — ESI and its client plans must offer the prescriber a peer-to-peer call with the reviewing clinician. This step alone reverses a significant portion of PA denials. 5. If denied again, file for external review promptly.
## Documentation to Gather
- Diagnosis confirmation: DSM-5 opioid use disorder diagnosis, severity specifier, date, and treating clinician.
- Prior treatment history: Documentation of prior MOUD treatment — formulations tried, duration, outcomes, and clinical rationale for transitioning to or initiating Sublocade.
- Prescriber certification: Confirmation that the prescribing clinician holds the appropriate DEA registration or certification to prescribe buprenorphine for OUD.
- Clinical necessity letter: A detailed letter from the prescriber explaining why Sublocade is medically appropriate for this individual, referencing the FDA-approved prescribing information and applicable ASAM/SAMHSA guidelines generically.
- Patient-specific factors: Documentation of any adherence challenges, safety considerations, or clinical factors that support the injectable extended-release formulation over sublingual alternatives.
## Criteria-Mapping Structure
| ESI PA Criterion | Submitted Documentation | |---|---| | Confirmed OUD diagnosis | [DSM-5 criteria, date, clinician] | | Prior MOUD treatment documented | [Dates, formulations, outcomes] | | Prescriber credential verified | [DEA-X or applicable registration] | | Clinical rationale for Sublocade | [Prescriber letter with patient-specific factors] | | Consistent with FDA-approved labeling | [Prescriber attestation] |
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →